Company intelligence / Profile preview

2A Biosciences

Santa Monica, California, United States

Ownership: Private
Development stage: Preclinical

Overview

Developing non-hallucinogenic modulators of the serotonin 5‑HT2A receptor to treat chronic inflammatory diseases, starting with skin conditions like psoriasis and atopic dermatitis. Their approach aims to modify disease rather than just suppress symptoms, differentiating from current therapies. No clinical results have been published yet.

Therapeutic areas: DermatologyImmunology
Modalities: Small molecules or novel chemical entities targeting serotonin receptors (specifically non-hallucinogenic compounds acting on the 5-HT2A receptor)
Industry: Biotech

Partnerships

Tabula Rasa Ventures (investor/partner)

Beyond the preview

Go deeper on 2A Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2A Biosciences.

Explore the full profile